open access
Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)
open access
Abstract
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80
Abstract
MATERIAL AND METHODS: We retrospectively evaluated 19 patients (6 females and 13 males; median age: 61 years ± 15 standard deviation) affected by GIST histologically documented after surgical intervention or biopsy.
RESULTS: F18-FDG-PET/CT had identified pathologic uptakes and was considered positive for neoplastic tissue in 10 patients (53%) and negative in 9 (47%), in concordance with radiological findings.
CONCLUSIONS: F18-FDG-PET/CT is a feasible, reliable, and accurate method to restage patients affected by previously histologically confirmed GIST, also in the absence of a staging study.
Nuclear Med Rev 2010; 13, 2: 76–80
Keywords
positron emission tomography; PET; gastrointestinal stromal tumours; GIST; imatinib mesylate
About this articleTitle
Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)
Journal
Issue
Pages
76-80
Published online
2011-05-20
Bibliographic record
Nucl. Med. Rev 2010;13(2):76-80.
Keywords
positron emission tomography
PET
gastrointestinal stromal tumours
GIST
imatinib mesylate
Authors
Francesco Bertagna
Giovanni Bosio
Emanuela Orlando
Giorgio Biasiotto
Raffaele Giubbini